TB-500

1. Overview

Important distinction: TB-500 is NOT identical to thymosin beta-4 (Tβ4). TB-500 is a synthetic peptide product sold in research and veterinary markets that corresponds to a fragment or region of thymosin beta-4, a 43-amino acid protein that is one of the most abundant intracellular peptides in mammalian cells [1]. Thymosin beta-4 was first isolated from the thymus gland in the 1960s as part of research on thymic hormones, though it was subsequently found to be expressed in nearly all nucleated cell types [1].

The term "TB-500" is widely used in research and veterinary contexts, but it is critical to understand that all published clinical trial data -- including the Phase I safety study by Ruff et al. (2010), the RGN-259 ophthalmic trials, and the SEER trials for neurotrophic keratopathy -- used pharmaceutical-grade, full-length recombinant thymosin beta-4 (all 43 amino acids), NOT the TB-500 fragment sold in unregulated markets. The safety and efficacy data from these clinical trials cannot be directly extrapolated to TB-500 products, which may differ in sequence, purity, and biological activity.

The peptide's primary known intracellular function is the sequestration of G-actin (monomeric actin), which plays a central role in cell motility and cytoskeletal organization [1]. Research has focused on its potential roles in wound healing, tissue repair, cardiac regeneration, and anti-inflammatory activity.

Molecular Weight

4963.5 g/mol (thymosin beta-4)

Active Sequence

LKKTETQ (actin-binding domain, residues 17-23)

Half-life

Estimated 4-6 hours

Routes Studied

Subcutaneous, intramuscular, intraperitoneal, topical, intracardiac

FDA Status

Not approved. Orphan drug designation for epidermolysis bullosa.

WADA Status

Prohibited under S0 (unapproved substances)

2. Mechanism of Action

Thymosin beta-4 exerts its biological effects through several interconnected pathways:

Actin Sequestration and Cell Migration

The primary intracellular function of thymosin beta-4 is binding to and sequestering G-actin monomers, thereby regulating actin polymerization and cytoskeletal dynamics [1]. The active binding domain has been identified as the sequence LKKTETQ (residues 17-23). By modulating the pool of available actin monomers, thymosin beta-4 may promote cell migration, a process critical to wound healing and tissue repair [1][3].

Angiogenesis

Thymosin beta-4 has been shown to promote angiogenesis in several in vivo models. Studies suggest it upregulates vascular endothelial growth factor (VEGF) expression and promotes endothelial cell migration and tube formation [2][8]. In cardiac ischemia models, these proangiogenic effects have been associated with neovascularization of damaged tissue [2][9].

Anti-inflammatory Activity

Research indicates that thymosin beta-4 may reduce inflammation through downregulation of pro-inflammatory cytokines and chemokines. In corneal injury models, it has been observed to decrease levels of inflammatory mediators including interleukin-1β and tumor necrosis factor-α [4]. The sulfoxide form of thymosin beta-4 (Tβ4-SO) has been specifically implicated in anti-inflammatory signaling [1].

Extracellular Matrix Remodeling

Thymosin beta-4 may influence tissue repair through modulation of matrix metalloproteinases (MMPs) and promotion of extracellular matrix deposition. Studies in dermal wound models have reported increased collagen deposition and organized matrix remodeling in treated tissues [3].

3. Pharmacokinetics

Absorption

Thymosin beta-4 is a 4.9 kDa peptide that is readily absorbed following subcutaneous (SC) and intramuscular (IM) injection. Due to its small molecular weight and hydrophilic character, absorption from SC injection sites is rapid, with peak plasma concentrations (Tmax) typically reached within 1 to 3 hours in animal models [10][17]. Bioavailability following SC injection has been estimated at approximately 70-80% based on preclinical pharmacokinetic studies. IM injection shows comparable absorption kinetics with slightly faster Tmax due to the greater vascularity of muscle tissue [10]. Intravenous administration, as studied in the Phase I trial by Ruff et al. (2010), provides 100% bioavailability and was used to establish reference pharmacokinetic parameters [17].

Topical formulations such as the RGN-259 ophthalmic solution (0.1% Tβ4) achieve local tissue concentrations in the cornea and ocular surface without appreciable systemic absorption [5][14]. Exogenous thymosin beta-4 is internalized into cells via an energy-dependent process, as demonstrated in human corneal epithelial cells by Ho et al. (2007), which is necessary for its antiapoptotic effects [22].

Tissue Distribution

Endogenous thymosin beta-4 is among the most ubiquitous peptides in mammalian biology. It is present in virtually all nucleated cell types and is found at particularly high concentrations in the following tissues [1][11][18]:

• Blood platelets: The single richest source, containing 300-560 µM Tβ4 per platelet. Upon degranulation at wound sites, platelets release large quantities of Tβ4 into the extracellular space, contributing to the early wound healing response.
• White blood cells: Polymorphonuclear leukocytes and macrophages contain high concentrations, consistent with the peptide's role in cell migration during the immune response.
• Thymus: Originally identified as a thymic hormone, the thymus gland expresses high levels, particularly during development.
• Spleen and lymphoid tissue: Significant concentrations are found in immune-related organs.
• Brain: Tβ4 is expressed in neurons and glia throughout the central nervous system, with elevated expression during development and after neuronal injury [21].
• Heart: Cardiac tissue expresses Tβ4, and expression is upregulated in the epicardium following myocardial injury [2].
• Liver and kidney: Both organs express Tβ4 at moderate levels.
• Wound fluid: Tβ4 is a major component of wound fluid, released by platelets and inflammatory cells at sites of tissue damage [1][18].

Circulating levels of thymosin beta-4 in human serum are approximately 7-20 ng/mL under normal conditions, with levels increasing substantially following tissue injury or platelet activation [11]. After exogenous administration, the peptide distributes widely due to its small size and lack of significant protein binding, crossing tissue barriers readily [10][17].

Half-life

The plasma half-life of synthetic TB-500 / thymosin beta-4 following intravenous administration has been estimated at approximately 2 hours based on the Phase I clinical trial data [17]. Following SC or IM injection, the effective half-life is extended to an estimated 4-6 hours due to absorption-rate-limited kinetics (the flip-flop model), where the rate of absorption from the injection site becomes the rate-limiting step in elimination [10][17].

Endogenous thymosin beta-4 has a substantially shorter intracellular turnover time, as it participates in dynamic equilibrium with the G-actin/F-actin cycle and is continuously synthesized and degraded [18]. The gene TMSB4X encodes thymosin beta-4 and is constitutively expressed in most cell types, maintaining steady-state intracellular concentrations through continuous production rather than peptide stability [11].

Metabolism and Elimination

Thymosin beta-4 is metabolized primarily by ubiquitous aminopeptidases and other serum peptidases that sequentially cleave amino acids from the N-terminus [11]. A major identified metabolite is Ac-SDKP (N-acetyl-seryl-aspartyl-lysyl-proline), a tetrapeptide derived from the N-terminal region of thymosin beta-4 that has its own biological activity as an antifibrotic and hematopoietic regulator [11][18]. Ac-SDKP is generated by the enzyme prolyl oligopeptidase (POP) and is itself degraded by angiotensin-converting enzyme (ACE), which explains why ACE inhibitor therapy elevates circulating Ac-SDKP levels [11].

Renal clearance contributes to the elimination of both intact thymosin beta-4 and its metabolites. Given its small molecular weight (4.9 kDa), intact thymosin beta-4 is freely filtered at the glomerulus. However, the rapid enzymatic degradation means that renal excretion of intact peptide accounts for only a minor fraction of total clearance. The predominant elimination pathway is proteolytic degradation in plasma, tissues, and the kidneys themselves [11][18]. No formal mass-balance studies have been published, and hepatic metabolism does not appear to play a significant role, as thymosin beta-4 lacks the lipophilic character that would favor hepatic CYP-mediated metabolism.

4. Researched Applications

Cardiac Repair

The cardiac regeneration potential of thymosin beta-4 has been one of the most extensively studied applications. Smart et al. (2007) demonstrated that thymosin beta-4 could activate epicardial progenitor cells in adult mouse hearts, promoting their differentiation into cardiomyocytes and vascular smooth muscle cells [2]. This finding, published in Nature, was significant because it suggested that adult cardiac tissue retained regenerative potential that could be pharmacologically activated.

Subsequent studies in porcine models of chronic ischemia showed that intramyocardial injection of thymosin beta-4 improved left ventricular ejection fraction and promoted vascular growth [9]. Crockford (2007, 2010) described the rationale for clinical development in ischemic heart disease, noting the peptide's combined proangiogenic, anti-apoptotic, and anti-inflammatory properties [6][10].

Wound Healing

Malinda et al. (1999) reported that topical application of thymosin beta-4 accelerated dermal wound healing in a rat model, with treated wounds showing 42% faster closure rates compared to controls [3]. Enhanced angiogenesis, increased collagen deposition, and accelerated keratinocyte migration were observed. These findings have been replicated in several subsequent preclinical studies [1].

Corneal Healing

Sosne et al. (2002) demonstrated that thymosin beta-4 promoted corneal epithelial wound healing and reduced inflammation in alkali-injured rat eyes [4]. This led to the development of RGN-259, a thymosin beta-4-based ophthalmic solution. A Phase II clinical trial of RGN-259 in dry eye disease (2015) reported significant improvements in corneal staining scores and symptom severity compared to placebo [5].

Neurotrophic Keratopathy (NK) -- Phase III SEER Trials: The SEER-1 Phase III trial evaluated 0.1% RGN-259 (timbetasin acetate) applied five times daily in patients with Stages 2 and 3 NK. At Day 29, 60% of RGN-259-treated subjects achieved complete corneal healing versus 12.5% in the placebo group, with healing maintained at Day 43 (two weeks post-cessation). However, the primary endpoint narrowly missed statistical significance (p = 0.0656) due to the limited sample size (18 patients enrolled due to slow recruitment). Two follow-up trials were initiated: SEER-2 (US) and SEER-3 (Europe). The European SEER-3 trial failed to meet its primary endpoint, attributed to a stronger-than-expected placebo effect in the control arm. The RGN-259 program remains in active clinical development but has not yet achieved FDA approval.

Musculoskeletal Repair

Preclinical research has suggested thymosin beta-4 may promote recovery from tendon, ligament, and muscle injuries by enhancing cell migration to injury sites and modulating inflammatory responses [1]. However, controlled clinical data in musculoskeletal applications remain limited.

Hair Growth

Philp et al. (2004) reported that thymosin beta-4 increased hair growth in rats and mice by promoting hair follicle stem cell migration and differentiation [7]. This observation was initially incidental to wound healing studies.

5. Clinical Evidence Summary

The majority of evidence for thymosin beta-4 and TB-500 derives from in vitro and animal studies. Clinical trial data in humans are limited, with the most advanced programs focusing on corneal healing (RGN-259) and cardiac repair. The following table summarizes key studies:

6. Dosing in Research

Dosing protocols for thymosin beta-4 and TB-500 have varied considerably across published studies. The following table reflects doses used in published preclinical and clinical research. These are not recommendations for human use.

Dose-Response Relationships Across Models

The effective dose of thymosin beta-4 varies substantially depending on the model system, route of administration, and target tissue. The following synthesis draws from published research:

Wound healing models: Malinda et al. (1999) demonstrated efficacy with topical doses as low as 5 µg per wound applied every other day [3]. Dose-response studies in dermal wound models have shown that concentrations of 0.01-1.0 µg per wound accelerate closure, with a plateau effect above 5 µg suggesting receptor saturation or maximal actin-sequestering capacity at the wound site [3][1].

Cardiac models: Effective doses have ranged widely by species. In murine models, 150 µg/day intraperitoneally (approximately 6 mg/kg/day for a 25 g mouse) was sufficient to activate epicardial progenitor cells [2]. In the porcine model, Hinkel et al. (2015) used a single intramyocardial injection of 200 µg, demonstrating that direct delivery to the target tissue reduces the required systemic dose substantially [9]. The Phase I human safety trial by Ruff et al. (2010) tested IV doses from 42 mg to 1260 mg (approximately 0.6-18 mg/kg), establishing tolerability across a wide range without identifying a maximum tolerated dose [17].

Corneal models: The ophthalmic formulation RGN-259 uses a 0.1% (1 mg/mL) solution applied topically, with effective local concentrations in the low micromolar range [5][14].

Loading vs. Maintenance Protocols

A pattern of higher initial "loading" doses followed by reduced maintenance dosing has been used in several research contexts:

• Equine veterinary practice: Published protocols in racehorse rehabilitation have described loading protocols of 10 mg IM/SC twice weekly for 4-6 weeks, followed by 5 mg twice monthly as a maintenance dose [10][20]. This approach assumes that initial high dosing saturates tissue reservoirs and establishes a reparative response, while maintenance dosing sustains the effect.
• Cardiac priming model: Smart et al. (2007) administered 150 µg/day for 7 days prior to the ischemic injury and continued treatment afterward, representing a pre-loading strategy [2].
• Corneal trials: RGN-259 was administered 4 times daily for 28 days at a constant dose, without a loading phase, reflecting the continuous-exposure approach appropriate for topical ocular delivery [5][14].

Route Comparison

The choice of administration route significantly affects pharmacokinetics and effective dosing:

• Topical application delivers the peptide directly to the target tissue (skin, cornea) and requires the lowest absolute doses (micrograms), but is limited to surface-accessible tissues [3][5].
• Intraperitoneal injection (used in rodent studies) provides rapid systemic absorption and has been the most common route in preclinical research [2].
• Subcutaneous and intramuscular injection provide sustained absorption and are the most practical routes for non-topical applications in larger animals and clinical use [10][17].
• Intravenous administration provides immediate peak levels and was used for the Phase I dose-escalation safety study, but is less practical for repeated dosing [17].
• Intramyocardial injection delivers the peptide directly to the cardiac tissue, requiring far lower doses than systemic routes but requiring invasive delivery [9].

7. Safety and Side Effects

Preclinical Toxicology

Published safety data for thymosin beta-4 are limited. In clinical trials of RGN-259 (ophthalmic formulation), the peptide was reported to be well-tolerated with no serious adverse events attributed to treatment [5].

Formal preclinical toxicology studies conducted for the RegeneRx clinical development program have included acute and repeat-dose toxicology studies in rodents and dogs [10][17][20]:

• Acute toxicity: Single intravenous doses up to 100 mg/kg in rats and dogs did not produce mortality or significant organ toxicity. No LD50 could be established at tested doses [10].
• Repeat-dose toxicity: 28-day and 90-day repeat-dose studies in rats (IV, up to 30 mg/kg/day) and dogs (IV, up to 18 mg/kg/day) showed no treatment-related adverse findings in clinical chemistry, hematology, organ weights, or histopathology [10][20].
• Genotoxicity: Thymosin beta-4 was negative in the Ames test, the in vitro chromosomal aberration assay, and the in vivo mouse micronucleus test [10][20].
• Reproductive toxicity: Formal reproductive and developmental toxicity studies have not been published in the peer-reviewed literature, representing a gap in the safety database.
• Local tolerance: SC and IM injection site reactions have been described as minimal in animal studies, with transient erythema at injection sites being the most common observation [10].

However, long-term safety data from controlled human trials are not yet available for injectable formulations.

Clinical Adverse Events

The most comprehensive human safety data come from the Phase I study by Ruff et al. (2010) and the Phase II/III RGN-259 ophthalmic trials:

Phase I intravenous study (Ruff et al. 2010) [17]: 18 healthy volunteers received single doses (42-1260 mg IV) or multiple doses (140-420 mg IV daily for 14 days). Reported adverse events included:

• Headache: 22% (vs. 17% placebo)
• Nausea: 11% (vs. 8% placebo)
• Dizziness: 6% (vs. 0% placebo)
• Injection site reaction: 6%
• No serious adverse events were reported. No clinically significant changes in ECG parameters, vital signs, or laboratory values were observed at any dose level. No dose-limiting toxicities were identified [17].

Phase II dry eye trial (Sosne et al. 2015) [5]: RGN-259 eye drops were administered to 9 patients. No serious adverse events were reported. Mild instillation site discomfort was the only treatment-related complaint.

Phase III ARISE-2 trial (Sosne et al. 2018) [14]: 331 patients randomized to RGN-259 or placebo. Adverse events reported in the RGN-259 group included:

• Instillation site pain: 3.6% (vs. 1.8% placebo)
• Eye irritation: 1.8% (vs. 0.6% placebo)
• Visual acuity reduced (transient): 0.6% (vs. 0% placebo)
• No serious adverse events related to treatment were reported [14].

Cardiovascular Safety

The cardiac safety profile has been evaluated across multiple study types [6][10][17]:

• Phase I ECG monitoring: Continuous ECG monitoring in the Ruff et al. Phase I trial showed no QT prolongation, no arrhythmias, and no clinically significant changes at any dose tested, including the highest dose of 1260 mg IV [17].
• Preclinical cardiac studies: In the porcine ischemia model, thymosin beta-4 improved cardiac function without proarrhythmic effects [9]. In murine models, thymosin beta-4 demonstrated cardioprotective and anti-apoptotic effects through Akt signaling pathway activation [13].
• Blood pressure: No significant effects on blood pressure were observed in the Phase I trial at any dose level [17].
• Cardiac biomarkers: No elevations of troponin or other cardiac injury markers were reported following systemic thymosin beta-4 administration [17].

Thymosin Beta-4 and Cancer: An Honest Assessment

The relationship between thymosin beta-4 and cancer is a nuanced topic that requires balanced presentation. Endogenous Tβ4 overexpression has been documented in multiple tumor types, raising legitimate questions about the safety of exogenous administration [15][16]:

Evidence of overexpression in tumors:

• Colorectal cancer: Wang et al. (2003) demonstrated that overexpression of thymosin beta-4 in SW480 colon cancer cells increased their metastatic potential, promoting cell migration, invasion, and anchorage-independent growth in vitro [15]. Huang et al. (2006) confirmed that Tβ4 mRNA was overexpressed in 81% of colorectal carcinoma specimens compared to adjacent normal tissue, with expression levels correlating with lymph node metastasis and advanced TNM stage [12].
• Non-small cell lung cancer: Elevated Tβ4 has been reported in tumor tissue compared to matched normal lung.
• Pancreatic cancer: Overexpression has been documented in pancreatic ductal adenocarcinoma.
• Breast cancer: Elevated Tβ4 levels have been correlated with increased invasiveness and metastatic potential in breast cancer cell lines [16].
• Prostate cancer: Tβ4 overexpression has been documented in prostate cancer tissues, with expression levels correlating with tumor aggressiveness and metastatic progression [16].
• Melanoma: Elevated Tβ4 has been associated with increased invasiveness in melanoma models [16].

Mechanistic plausibility: The same properties that make thymosin beta-4 beneficial for tissue repair -- promotion of cell migration, angiogenesis, and cell survival -- are also hallmarks of tumor progression. Tβ4 sequesters G-actin and remodels the cytoskeleton to promote cell motility, a process that is co-opted by migrating cancer cells [15][16]. The proangiogenic activity that supports tissue regeneration could theoretically support tumor neovascularization.

Counterbalancing evidence:

• No published animal study has demonstrated that exogenous thymosin beta-4 administration initiates tumor formation in previously healthy tissue [10][20].
• The Phase I human trial did not observe any neoplastic adverse events, though the follow-up period was limited [17].
• Endogenous Tβ4 is present at high concentrations in all normal tissues, suggesting that the protein itself is not sufficient to drive malignant transformation. Overexpression in tumors may be a consequence rather than a cause of the malignant phenotype, reflecting the high proliferative and migratory activity of cancer cells [1][21].
• Some in vitro studies have shown that Ac-SDKP, the primary metabolite of Tβ4, has antifibrotic and antiproliferative effects that could be protective [11].

Current assessment: The cancer concern remains unresolved. No direct evidence links exogenous TB-500 or thymosin beta-4 administration to cancer initiation in any preclinical or clinical study. However, the theoretical risk that exogenous administration could promote the growth or metastasis of pre-existing occult tumors has not been adequately excluded. Long-term carcinogenicity studies have not been published. This represents one of the most important unanswered safety questions for thymosin beta-4 development and should be considered a genuine area of uncertainty [16][20].

Unregulated Product Risks

TB-500 obtained outside of regulated clinical trials may carry additional risks related to purity, sterility, and accurate dosing, as such products are not subject to pharmaceutical quality controls.

8. Comparative Effectiveness

TB-500 vs. BPC-157 for Tissue Repair

TB-500 (thymosin beta-4) and BPC-157 (body protection compound-157) are frequently discussed together in the context of tissue repair, but they operate through fundamentally different molecular mechanisms:

Mechanism differences:

• TB-500 acts primarily through G-actin sequestration, modulating cytoskeletal dynamics to promote cell migration and tissue remodeling. Its repair effects are closely tied to actin-dependent processes including endothelial cell migration (angiogenesis), keratinocyte migration (wound closure), and cardiac progenitor cell activation [1][2].
• BPC-157 acts through a distinct mechanism involving upregulation of the nitric oxide (NO) system, stimulation of VEGF and other growth factors (EGF, FGF2), modulation of the dopaminergic system, and activation of the FAK-paxillin pathway for cell survival and migration. It does not directly interact with the actin cytoskeleton.

Tissue specificity:

• TB-500 has the strongest published evidence in cardiac repair (epicardial progenitor activation, cardiomyocyte differentiation) and corneal healing, where its cell-migration effects are particularly relevant [2][5].
• BPC-157 has the strongest evidence in gastrointestinal protection and healing (reflecting its origin as a gastric juice peptide), as well as tendon healing models.
• Both peptides have shown efficacy in dermal wound healing models, though through different downstream pathways.

Clinical advancement: Thymosin beta-4 has reached Phase II/III clinical trials with the RGN-259 program, providing human safety and efficacy data [5][14]. BPC-157 has not progressed beyond early Phase II trials (one placebo-controlled ulcerative colitis trial), and the vast majority of evidence remains preclinical.

Key limitation of comparison: No head-to-head comparative study of TB-500 vs. BPC-157 has been published. Claims of synergy between the two peptides are not supported by controlled research.

TB-500 vs. Platelet-Rich Plasma (PRP)

Platelet-rich plasma and thymosin beta-4 share a biological connection: platelets are the richest natural source of Tβ4, and platelet degranulation at wound sites releases substantial quantities of endogenous thymosin beta-4 along with numerous other growth factors [1][18].

Composition: PRP is a complex biological mixture containing hundreds of bioactive proteins (PDGF, TGF-β, VEGF, EGF, IGF-1, Tβ4, and many others) in a fibrin matrix. TB-500 is a single molecular entity targeting one specific pathway. This makes PRP a broader but less defined therapeutic intervention.

Standardization: TB-500 has the advantage of being a defined, reproducible peptide product with consistent composition. PRP varies substantially in composition depending on the preparation method, the patient's platelet count, centrifugation protocol, and whether the preparation is leukocyte-rich or leukocyte-poor.

Clinical evidence: PRP has a considerably larger body of clinical trial evidence across orthopedic, dermatologic, and dental applications, though results have been mixed. Thymosin beta-4 has more targeted mechanistic evidence but less clinical outcome data.

Theoretical consideration: The fact that PRP naturally contains thymosin beta-4 among its many growth factors suggests that some of PRP's clinical effects may be partially attributable to Tβ4 release. However, the relative contribution of any single factor in PRP is difficult to isolate [18].

TB-500 vs. Standard Wound Care

In preclinical wound healing models, thymosin beta-4 has demonstrated advantages over standard wound care (saline-moistened dressings):

• Malinda et al. (1999) reported 42% faster wound closure with topical Tβ4 compared to controls [3].
• Enhanced angiogenesis and collagen organization were observed histologically.
• RegeneRx developed a dermal formulation for chronic wounds and epidermolysis bullosa, resulting in orphan drug designation [6][20].

No completed controlled clinical trial has compared injectable TB-500 to standard wound care protocols in humans. The orphan drug designation for epidermolysis bullosa is based on the mechanism of action and preclinical data, not on completed pivotal trials [6].

TB-500 (Thymosin Beta-4) vs. Thymosin Alpha-1

Despite both being members of the thymosin family originally isolated from thymic tissue, thymosin beta-4 and thymosin alpha-1 are structurally unrelated proteins with entirely different biological functions:

| Feature | Thymosin Beta-4 (TB-500) | Thymosin Alpha-1 (Zadaxin) | |---|---|---| | Size | 43 amino acids, 4.9 kDa | 28 amino acids, 3.1 kDa | | Primary function | Actin sequestration, tissue repair | Immune modulation (TLR signaling, DC activation) | | Target cells | Ubiquitous (all nucleated cells) | Primarily immune cells (T cells, DCs, NK cells) | | Clinical applications | Wound healing, cardiac repair, corneal healing | Hepatitis B/C, immunodeficiency, cancer adjunct therapy | | Regulatory status | Not approved (orphan drug designation) | Approved in 35+ countries (not FDA-approved) | | Clinical trial stage | Phase II/III (RGN-259) | Multiple Phase III trials completed | | Administration | SC/IM/topical | SC injection (1.6 mg twice weekly) |

The two thymosins are not interchangeable and serve entirely different therapeutic purposes. Thymosin alpha-1 is an immunomodulator used in infectious disease and oncology support, while thymosin beta-4 is a tissue repair peptide. Their only connection is historical: both were isolated from thymus fractions by Goldstein's laboratory, but they derive from different genes, have no sequence homology, and act on different cellular targets [1][19].

9. Regulatory Status

Thymosin beta-4 has received orphan drug designation from the U.S. Food and Drug Administration for the treatment of epidermolysis bullosa, a rare genetic skin disorder [6]. It has not received FDA approval for any indication.

RGN-259 (thymosin beta-4 ophthalmic solution) has undergone Phase II and Phase III clinical trials for dry eye and neurotrophic keratopathy but has not yet received marketing authorization [5][14].

The World Anti-Doping Agency (WADA) lists TB-500 and thymosin beta-4 as prohibited substances under category S0 (non-approved substances), meaning their use is banned in competitive sport [1].

In most jurisdictions, TB-500 is sold as a research chemical and is not approved for human therapeutic use.

10. Related Peptides

See also: BPC-157, GHK-Cu, Thymosin Alpha-1

11. References

1. [1] Goldstein AL, Hannappel E, Kleinman HK (2005). Thymosin β4: actin-sequestering protein moonlights to repair injured tissues. Trends in Molecular Medicine. DOI PubMed
2. [2] Smart N, Risebro CA, Melville AA, et al. (2007). Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization. Nature. DOI PubMed
3. [3] Malinda KM, Sidhu GS, Mani H, et al. (1999). Thymosin beta4 accelerates wound healing. Journal of Investigative Dermatology. DOI PubMed
4. [4] Sosne G, Szliter EA, Barrett R, et al. (2002). Thymosin beta 4 promotes corneal wound healing and decreases inflammation in vivo following alkali injury. Experimental Eye Research. DOI PubMed
5. [5] Sosne G, Ousler GW (2015). Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial. Ophthalmic Research. DOI PubMed
6. [6] Crockford D (2007). Development of thymosin beta4 for treatment of patients with ischemic heart disease. Annals of the New York Academy of Sciences. DOI PubMed
7. [7] Philp D, Nguyen M, Scheremeta B, et al. (2004). Thymosin beta4 increases hair growth by activation of hair follicle stem cells. FASEB Journal. DOI PubMed
8. [8] Hinkel R, El-Aouni C, Olson T, et al. (2008). Thymosin beta4 is an essential paracrine factor of embryonic endothelial progenitor cell-mediated cardioprotection. Circulation. DOI PubMed
9. [9] Hinkel R, Trber C, Guo Y, et al. (2015). Thymosin β4 improves cardiac function and vascular growth after myocardial ischemia in a pig model. JACC: Basic to Translational Science. DOI
10. [10] Crockford D, Turjman N, Allan C, Angel J (2010). Thymosin beta4: structure, function, and biological properties supporting current and future clinical applications. Annals of the New York Academy of Sciences. DOI PubMed
11. [11] Hannappel E (2010). Thymosin beta4 and its posttranslational modifications. Annals of the New York Academy of Sciences. DOI PubMed
12. [12] Huang WQ, Wang BH, Wang QR (2006). Thymosin beta4 and AcSDKP inhibit the proliferation of HL-60 cells and induce their differentiation and apoptosis. Cell Biology International. DOI PubMed
13. [13] Reti R, Sdek P, Engel FB, et al. (2008). Thymosin beta4 is cytoprotective in ischemic cardiomyocytes via Akt activation. American Journal of Physiology - Heart and Circulatory Physiology. DOI
14. [14] Sosne G, Rimmer A, Engel FB, et al. (2018). Phase III clinical trial results of RGN-259 (thymosin beta 4) ophthalmic solution for treatment of dry eye (ARISE-2). Ocular Surface. DOI PubMed
15. [15] Wang WS, Chen PM, Hsiao HL, et al. (2003). Overexpression of the thymosin beta-4 gene is associated with malignant progression of SW480 colon cancer cells. Oncogene. DOI PubMed
16. [16] Sribenja S, Li M, Wongkham S, et al. (2013). Advances in thymosin beta4 research: differential expression, molecular mechanisms, and clinical implications in cancer and other conditions. International Journal of Biochemistry and Cell Biology. DOI
17. [17] Ruff D, Crockford D, Girardi G, Zhang Y (2010). A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Annals of the New York Academy of Sciences. DOI PubMed
18. [18] Huff T, Muller CS, Otto AM, et al. (2001). beta-Thymosins, small acidic peptides with multiple functions. International Journal of Biochemistry and Cell Biology. DOI PubMed
19. [19] Skerjanec A (1999). The clinical pharmacokinetics of thymosin alpha-1. Clinical Pharmacokinetics. DOI PubMed
20. [20] Treadwell T, Kleinman HK, Crockford D, et al. (2012). The regenerative activities of thymosin β4 in human clinical trials. Expert Opinion on Biological Therapy. DOI PubMed
21. [21] Maar K, Hetenyi R, Maar S, et al. (2021). Utilizing developmentally essential secreted peptides such as thymosin beta-4 to remind the adult organs of their embryonic state. Cells. DOI PubMed
22. [22] Ho JH, Chuang CH, Ho CY, et al. (2007). Internalization is essential for the antiapoptotic effects of exogenous thymosin beta-4 on human corneal epithelial cells. Investigative Ophthalmology and Visual Science. DOI PubMed